| Identification | Back Directory | [Name]
2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- | [CAS]
2653994-08-0 | [Synonyms]
JDQ-443
NVP-JDQ443
JDQ443?(NVP-JDQ443)
JDQ-443 (Synonyms: NVP-JDQ443)
2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- | [Molecular Formula]
C29H28ClN7O | [MDL Number]
MFCD34578463 | [MOL File]
2653994-08-0.mol | [Molecular Weight]
526.04 |
| Chemical Properties | Back Directory | [Boiling point ]
737.3±60.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (475.26 mM; Need ultrasonic) | [form ]
Solid | [pka]
12.55±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
JDQ443 is a RAS GTPase family covalent inhibitor currently in phase II trial in patients with nonsmall cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy. | [General Description]
Class: non-kinase;
Treatment: KRAS(G12C) NSCLC;
Elimination half-life: 7 h | [target]
Primary targets: KRAS(G12C) |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://m.is0513.com/ShowSupplierProductsList927327/0.htm |
|